Novavax Inc (NASDAQ:NVAX) shares ticked 2.03% up to $1.51 on Monday but retreated 19.21% to $1.22 in after-hours trading. Share prices have been trading in a 52-week range of $0.73 to $8.49. The company has a market cap of $418.27 million at 282.61 million shares outstanding.
In a press release, Novavax Inc announced positive topline data from its Phase 2 safety and immunogenicity trial of the RSV F Vaccine in older adults. It also released new preclinical data on its RSV F Vaccine construct, additional findings from the prior Phase 2 and Phase 3 clinical trials in older adults.
“Since September, we have worked to confirm that our RSV F Vaccine elicits a broadly neutralizing antibody response. Through our E205 trial, we have demonstrated adjuvant strategies that magnify and enrich the quality of that underlying antibody response. When combined with the COPD data seen in both E301 and E201, we believe protecting individuals from COPD exacerbation presents a very exciting path forward in older adults,” said Gregory Glenn, M.D., President of R&D.
“The new data that further characterizes the RSV F Vaccine and the benefit of adjuvants, combined with the hospitalization data in the COPD population, places us in a strong position to partner our RSV program,” said Stanley C. Erck, Novavax Inc President and CEO. “We also look forward to continued momentum in Prepare trial enrollment and to developing our plans for the next steps in our RSV older adult program over the next 12 months.”
Novavax Inc is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The company operates through developing recombinant vaccines segment.
Through its recombinant nanoparticle vaccine technology, Novavax Inc produces vaccine candidates to respond to both known and newly emerging diseases. The Company’s product pipeline focuses on a range of infectious diseases with vaccine candidates in clinical development for respiratory syncytial virus, seasonal influenza, pandemic influenza and the Ebola virus.
Its lead adjuvant for human applications, Matrix-M, is in a Phase I/II clinical trial for pandemic influenza H7N9 vaccine candidate. It is also testing Matrix-M in conjunction with its EBOV vaccine candidate in a Phase I clinical trial. It is developing additional pre-clinical stage programs in a range of infectious diseases, including Middle East respiratory syndrome.